| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 3 securities · passive | ||||||
|
Outlook Therapeutics, Inc.
13G/A
OTLK · 69012T305
|
6.4% |
2/14/2025
Event 12/31/2024
|
||||
| Tang Capital Management, LLC | 6.4% | |||||
| Kevin Tang | 6.4% | |||||
| Tang Capital Partners, LP | 5.9% | |||||
| Tang Capital Partners III, Inc | 0.5% | |||||
| Tang Capital Partners IV, Inc | 0% | |||||
|
Marinus Pharmaceuticals, Inc.
13G/A
MRNS · 56854Q200
|
3.0% |
2/14/2025
Event 12/31/2024
|
||||
| Tang Capital Management, LLC | 3.0% | |||||
| Kevin Tang | 3.0% | |||||
| Tang Capital Partners, LP | 2.4% | |||||
| Tang Capital Partners III, Inc | 0.6% | |||||
| Tang Capital Partners IV, Inc | 0% | |||||
|
ALX Oncology Holdings, Inc.
13G/A
ALXO · 00166B105
|
6.3% |
2/14/2025
Event 12/31/2024
|
||||
| Tang Capital Management, LLC | 6.3% | |||||
| Kevin Tang | 6.3% | |||||
| Tang Capital Partners, LP | 6.3% | |||||
| Tang Capital Partners III, Inc | 0% | |||||
| Tang Capital Partners IV, Inc | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.